Phenogen Sciences, Inc., the U.S. subsidiary firm of Genetic Technologies Limited (ADR) (NASDAQ:GENE) and manufacturer of BREVAGenplus expressed its views on the American Cancer Society’s recent modifications to breast cancer screening recommendations. These guidelines are aimed at women having an average risk of breast cancer.
The details
The subsidiary firm of Genetic Technologies revised the advised age for first mammogram to forty-five and advised women over age fifty-fiveopt for biennial mammograms. However, the guidelines also brings clinical uncertainty by stating that women in age group of between 40 and 44 years should still have an option to get yearly mammograms, and that women fifty-five years and older should have the opportunity to opt for annual screenings.BREVAGenplus, which is a clinically-supported, genetically-based breast-cancer risk evaluation test, can assist physicians resolve this uncertaintyby categorizing which women warrant earlier or more frequent screening.
The management speaks
Eutillio Buccilli, the Chief Executive Officer of Genetic Technologies Limited (ADR) (NASDAQ:GENE), said that the American Cancer Society new modifications to breast cancer screening recommendations highlights a challenge for physicians to classify who is apt for mammography screening before 45 years and yearly after age 55. Buccilli added that BREVAGenplus provides a solution, by offering physicians with a better assessment of a patient’s risk of getting sporadic breast cancer.
The highlights
The CEO of Genetic Technologies further added that BREVAGenplus assessment can help direct patients and physicians about a more personalized breast cancer screening program. More than 85% of women diagnosed with breast cancer presents little or no family history of breast cancer and may have been ignored for mammography screening earlier. BREVAGenplus test evaluates both genetic markers as well as clinical risk factors known to be related with non-hereditary, or sporadic, breast cancer to identify a woman’s risk of developing the breast cancer. This test is planned to encourage better informed decisions related to breast cancer screening.
